Table 2 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
收藏数据链接：
官方服务：
资源简介：
Summary of investigator-assessed best response without confirmation (mITT population and PD-L1 CPS ≥ 20 subgroup).
创建时间：
2026-03-16
